Search Results: C-THR88-2405 Valid Vce 🦊 C-THR88-2405 Practice Test Online 🎶 Guaranteed C-THR88-2405 Questions Answers 🕑 Easily obtain ➤ C-THR88-2405 ⮘ for free download through ☀ www.pdfvce.com ️☀️ 😒C-THR88-2405 Valid Test Vce Free

Longitudinal monitoring for minimal residual disease (MRD) Cell3™ Target: Custom MRD Panels Small, ultrasensitive, personalized next generation sequencing (NGS) panels for detecting tumor specific variants at multiple time points. Request a quote Product datasheet Personalized panels designed in minutes An on-line panel design tool and rapid manufacture process enables fast turnaround of highly targeted tumor…

Our Technology Nonacus has developed two proprietary technologies Cell3™ Target and GALEAS™. Cell3™ Target focuses on target enrichment technology generating next generation sequencing (NGS) libraries from all DNA types (gDNA, FFPE and cfDNA). GALEAS™ is an innovative platform combining ultra-sensitive genomic technology with sophisticated bioinformatic tools for diagnostic reporting. Unleash the power of precision with…

Comprehensive test for hereditary cancer GALEAS™ HereditaryPlus A clinically validated NGS panel with optimized bioinformatics for analyzing germline mutations associated with hereditary cancers – including Lynch syndrome. Request a quote Product datasheet Complete hereditary cancer analysis at your fingertips. Streamline your testing from sample to data analysis. Between 5-10% of all cancers, including those of…

SCIENTIFIC WRITER Celina Whalley, MSc Celina Whalley is a scientific writer with expertise in genomics, residing in West Midlands, UK. 20+ years of experience working with University Genomic Service laboratories specializing in: RNA, DNA and cfDNA extraction, along with QC, from biological samples Microarrays for methylation, genotyping, and gene expression Next Generation Sequencing (NGS) library…

Carrier Screening for pediatric recessive disorders Cell3™ Target: Carrier Screening panel Accurately analyze carrier status of 448 inherited childhood disorders using a single workflow. Request a quote Comprehensive content Designed to enrich for genes with high clinical significance in a broad range of rare, highly penetrant recessive childhood disorders. Streamlined workflow Consolidate multiple technology workflows…

Privacy Notice This privacy notice is for this website www.nonacus.com and served by Nonacus Ltd and governs the privacy of its users who choose to use it Nonacus website Privacy Notice: effective as of 15/03/2024 Nonacus values your privacy and confidentiality of your Personal Data. We are committed to treating your Personal Data with care,…

Technical Support Request If you have any questions about our products or how we can assist you in tailoring your DNA tests, please feel free to contact us via the enquiry form, email, or phone. Contact Information Nonacus Address Unit 5, quinton business park, 11 Ridgeway, Quinton, Birmingham B32 1AF, United Kingdom Follow Us Send…

Contact us If you have any questions about our products or how we can assist you in tailoring your DNA tests, please feel free to contact us via the enquiry form or email. Technical support Nonacus address Unit 5, Quinton Business Park,                    11 Ridgeway, Quinton, Birmingham, …

Germline Panels Next generation sequencing (NGS) panels specifically designed for accurate cytogenetics analysis. Conventional methods for assessing chromosomal abnormalities associated with germline disorders require multiple tests from FISH and karyotyping, to MLPA and microarrays. Our NGS solutions consolidate these workflows, combining the analysis of SNVs, INDELs and CNVs, into a single assay, saving you time…

NGS profiling for both lymphoid and myeloid disorders Cell3™ Target: PanHemeOnc Panel Streamlining genetic testing for hematological malignancies Request a quote Testing for myeloid and lymphoid malignancies needs to be fast Successful treatment and improved prognosis of hematological cancer is directly impacted by the speed and efficacy of diagnosis.1 The complexity of hematological malignancies often…